Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.49 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29745194 | 1.00 | MAPT (0.58) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL5203786 | 0.88 | ALDH1A1 (0.60) | MAPTALDH1A1LMNAKCNH2MEN1 | |
| SCHEMBL4460142 | 0.87 | MAPT (0.59) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL1247295 | 0.87 | MAPT (0.59) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL23123966 | 0.86 | ALDH1A1 (0.43) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL23123008 | 0.86 | ALDH1A1 (0.43) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL29745366 | 0.86 | ALDH1A1 (0.43) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL3854881 | 0.86 | MAPT (0.58) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL26351952 | 0.85 | ALDH1A1 (0.57) | MAPTALDH1A1LMNASMARCA2SMARCA4 | |
| SCHEMBL6845367 | 0.84 | MAPT (0.56) | MAPTALDH1A1LMNASMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238598-A2 | STAT DEGRADERS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-3755688-B1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S A (PL) | 2023-06-14 | — | — | EP | disclosed |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2019162306-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | ADAMED PHARMA S.A. (PL) | 2019-08-29 | — | — | WO | disclosed |
| EP-3530651-A1 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS | Adamed sp. z o.o. (PL) | 2019-08-28 | — | — | EP | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20080214562-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| EP-1904501-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20080045537-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1853604-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1789045-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007008539-A2 | PYRANOPYRIDINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006096444-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006023400-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214562-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | MAPT 3212/4885ALDH1A1 2428/4885LMNA 4465/4885 |
| US-20080045537-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | MAPT 3251/4885ALDH1A1 2253/4885LMNA 4429/4885 |
| US-20090093454-A1 | Chemical Compounds | SLC10A1, CYP11B2, CYP4F3 | MAPT 923/4885ALDH1A1 286/4885LMNA 2628/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | MAPT 483/4885ALDH1A1 1096/4885LMNA 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.